Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT03322995

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

Led by Medical College of Wisconsin · Updated on 2026-01-08

125

Participants Needed

1

Research Sites

727 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.

CONDITIONS

Official Title

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be 18 years of age or older.
  • Able to understand and provide written informed consent or have a legally authorized representative.
  • Eastern Cooperative Group (ECOG) performance status less than 2.
  • Histologically confirmed pancreatic adenocarcinoma with biopsy completed before treatment.
  • Clinical stage consistent with resectable or borderline resectable pancreatic adenocarcinoma based on CT or MRI.
  • Adequate organ and bone marrow function, including specified blood cell counts and liver and kidney function.
  • CA19-9 biomarker level greater than 35 U/mL when total bilirubin is less than 2 mg/dL.
  • Female patients must be postmenopausal, surgically sterile, or have a negative pregnancy test and use contraception during and after treatment.
  • Male patients must be surgically sterile or use barrier contraception during and after treatment.
Not Eligible

You will not qualify if you...

  • Received more than two months of FOLFIRINOX or mFOLFIRINOX chemotherapy as first-line therapy.
  • No documented CA19-9 value with total bilirubin less than 2 prior to starting chemotherapy.
  • Received chemotherapy or radiation within three years before enrollment.
  • History of other malignancies within three years except certain cured skin, cervical, or prostate cancers.
  • Uncontrolled serious illnesses, active infections, psychiatric illness, excessive obesity (BMI over 55), or inability to comply with study.
  • Known infection with HIV, hepatitis B, or hepatitis C.
  • Pregnant or breastfeeding, or not using contraception if of childbearing potential.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

Loading map...

Research Team

M

Medical College of Wisconsin Clinical Cancer Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here